Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort.

Overview of attention for article published in Journal of Clinical Oncology, January 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

news: 3 news outlets
reddit: 1 Redditor

bluesky: 1 Bluesky user

Readers on

mendeley: 20 Mendeley

So far, Altmetric has seen 1 Bluesky post from an account with 461 followers.

Signatera tumor-informed ctDNA assay found to influence adjuvant chemotherapy decisions in 16.3% of stage II/III colorectal cancer cases, leading to de-escalation in 59.9%. This underscore ctDNA’s value in guiding treatment. Hoping MRD tests become stan…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.